MariMedMRMD +4.75% ROE % is -30.20% as of Mar. 2026. The stock has 5 warning signs investors should review. Among 936 Drug Manufacturers companies, MariMed ranks worse than 84.51% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. MariMed's annualized net income for the quarter that ended in Mar. 2026 was $-15.1 Mil. MariMed's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $50.1 Mil. Therefore, MariMed's annualized ROE % for the quarter that ended in Mar. 2026 was -30.20%.
The historical rank and industry rank for MariMed's ROE % or its related term are showing as below:
MRMD'
s ROE % Range Over the Past 10 Years
Min: -235.78 Med: -24.56 Max: 31.05
Current: -22.75
During the past 13 years, MariMed's highest ROE % was 31.05%. The lowest was -235.78%. And the median was -24.56%.
MRMD's ROE % is ranked worse than 84.51% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs MRMD: -22.75
MariMed (OTCPK:MRMD) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
MariMed ROE % Related Terms
MariMed ROE % Historical Data
* Premium members only.
The historical data trend for MariMed's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MariMed ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MariMed's ROE % distribution charts can be found below:
* The bar in red indicates where MariMed's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
MariMed (MRMD) has a ROE % of -30.20% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on MariMed and its competitors. According to the industry distribution chart, MariMed ranks #791 out of 936 companies in the Drug Manufacturers industry, placing it in the top 84.5%.
Is MariMed's ROE % too high?
MariMed's current ROE % is -30.20%. Based on the distribution chart, MariMed ranks #791 out of 936 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does MariMed's ROE % compare to CPHI and RMTI?
According to the Drug Manufacturers industry distribution chart, MariMed ranks #791 out of 936 companies for ROE %. This places MariMed in the lower half of its industry. The industry median ROE % is 5.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on MariMed and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MariMed's current ROE % is -30.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.16, compared to a current price of $0.07 — trading 54.5% below its estimated fair value. The current ROE % is -30.20%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For MariMed (MRMD), the current ROE % is -30.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRMD has been successfully added to your 